Market Overview:
The Antibody Drug Conjugates Market (ADC) market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to exhibit a CAGR of 14.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. ADCs work by attaching monoclonal antibodies to highly potent anti-cancer payloads or drugs. This allows delivery of the drug directly to the cancer cell, minimizing side effects. ADCs are being used for treatment of various blood cancers and solid tumors.
Market Dynamics:
Two main drivers of growth in the ADC market are 1) their preferential targeting of cancer cells over healthy cells, resulting in fewer side effects than traditional chemotherapy and 2) increasing pace of drug approvals and pipeline products in development. ADCs have shown promising clinical trial results with improved patient outcomes compared to conventional chemotherapy or biological drug treatments alone. Continued investments in R&D will further accelerate the development and availability of new ADC drugs.
Market key trends:
The Antibody Drug Conjugates (ADC) market has been witnessing high growth due to the increasing demand for targeted cancer therapies with improved safety and efficacy profiles. ADCs work by delivering cytotoxic anti-cancer drugs to tumor cells directly and sparing normal cells from chemotherapy-induced damage. The ability of ADCs to selectively kill cancer cells while minimizing adverse effects on healthy cells is accelerating their adoption over conventional chemotherapy. ADCs represent a major advance in personalized cancer treatment.
SWOT Analysis
Strengths: ADCs combine the targeting ability of monoclonal antibodies with the cancer-killing ability of chemotherapy drugs to treat various cancers more effectively with fewer side effects compared to conventional chemotherapy.
Weaknesses: High development costs, longer development timeline and manufacturing challenges associated with producing homogeneous ADC compounds at commercial scale.
Opportunities: Rising prevalence of cancer worldwide due to growing elderly population and sedentary lifestyles. Launch of novel ADC therapies targeting newly identified tumor antigens.
Threats: Patent expiries of major ADC brands posing pricing and market share challenges. Emergence of alternative targeted therapies such as bispecific antibodies and CAR-T cell therapies.
Key Takeaways
The Global Antibody Drug Conjugates Market size is expected to reach US$ 5.38 billion in 2023 and is anticipated to grow at a high CAGR of 14.2% to reach over US$ 14 billion by 2030.
Regional analysis: North America currently dominates the global ADC market owing to factors such as rising cancer incidence, favorable reimbursement policies and presence of leading market players. Asia Pacific is expected to exhibit fastest growth during the forecast period supported by growing healthcare expenditure, rising cancer awareness and expanding biotechnology industry.
Key players: Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
